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Summary Background Despite inherent differences between
the cytoskeletal networks of malignant and normal cells, and
the clinical antineoplastic activity of microtubule-directed
agents, there has yet to be a microfilament-directed agent
approved for clinical use. One of the most studied
microfilament-directed agents has been cytochalasin B, a
mycogenic toxin known to disrupt the formation of actin
polymers. Therefore, this study sought to expand on our pre-
vious work with the microfilament-directed agent, along with
other less studied cytochalasin congeners. Materials and
Methods We determined whether cytochalasin B exerted sig-
nificant cytotoxic effects in vitro on adherent M109 lung car-
cinoma and B16BL6 and B16F10 murine melanomas, or on
suspension P388/ADR murine leukemia cells. We also exam-
ined whether cytochalasin B, its reduced congener 21, 22-
dihydrocytochalasin B (DiHCB), or cytochalasin D could
synergize with doxorubicin (ADR) against ADR-resistant
P388/ADR leukemia cells, and produce significant cytotoxicity
in vitro. For in vivo characterization, cytochalasins B and D
were administered intraperitoneally (i.p.) to Balb/c mice chal-
lenged with drug sensitive P388-S or multidrug resistant P388/
ADR leukemias. Results Cytochalasin B demonstrated higher
cytotoxicity against adherent lung carcinoma and melanoma
cells than against suspension P388/ADR leukemia cells, as
assessed by comparative effects on cell growth, and IC50 and
IC80 values. Isobolographic analysis indicated that both cyto-
chalasin B and DiHCB demonstrate considerable drug synergy
with ADR against ADR-resistant P388/ADR leukemia, while
cytochalasin D exhibits only additivity with ADR against the
same cell line. In vivo, cytochalasins B and D substantially
increased the life expectancy of mice challenged with P388/S
and P388/ADR leukemias, and in some cases, produced long-
term survival. Conclusion Taken together, it appears that cyto-
chalasins have unique antineoplastic activity that could poten-
tiate a novel class of chemotherapeutic agents.
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Introduction
Cytochalasins are secondary mold metabolites that have been
shown in over three thousand publications to produce pro-
found pleotypic effects on normal and neoplastic cells, and on
tissues in culture. These effects appear to arise largely because
of the ability of various cytochalasin congeners to alter micro-
filament structure and function, and therefore to affect the
myriad of cell and tissue functions that are dependent on
microfilament biochemistry.
Cytochalasins alter cell motility, adherence, secretion, drug
efflux, deformability, morphology, and size, among many
other effects. Their influence on cell adherence includes alter-
ation of cell junctions leading to changes in tissue physiology
and transport. Moreover, they inhibit plasma membrane divi-
sion without similarly affecting nuclear division, thus produc-
ing multinucleated cells. For detailed references on cytocha-
lasins, see comprehensive reviews [1, 2] and for specific
references and further elaboration, see the preceding papers
in this series [3, 4].
The multinucleation phenomenon is more evident in neo-
plastic cells and less so in their normal counterparts, poten-
tially representing a neoplastic-targeting feature of cytochala-
sin mechanisms [5–12]. This apparent partial specificity of
cytochalasin action on neoplastic cells is consistent with a
separate body of evidence showing substantial differences in
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microfilament biochemistry between neoplastic and compara-
ble non-neoplastic cells [13]. These differences in microfila-
ment structures in turn may be related to key features of the
neoplastic phenotype, including altered adherence, anchorage
independent growth, invasiveness, and altered plasma mem-
brane cytoskeletal interactions involving in part expression of
oncogene products [14, 15].
It has been well documented that tumors often exhibit
innate or acquired resistance to chemotherapeutic agents due
to the overexpression of ATP-binding cassette (ABC) trans-
porters, which carry a substantial variety of compounds across
cellular compartments [14–16]. In particular, the plasma
membrane-spanning proteins, permeability glycoprotein (P-
gp) andmultidrug resistance-associated protein (MRP), confer
resistance to anthracyclines, taxanes, vinca alkaloids, and
other bulky chemotherapeutic agents due to drug efflux cata-
lyzed by the multi-drug resistance pump [17–19]. However,
cytochalasin B efflux is not potentiated by overexpression of
ABC transporters [20], a surprising finding given the struc-
tural bulk of the compound and its hydrophobicity. Due to its
novel mechanisms of action, it may be possible to use cyto-
chalasin B concomitantly with currently approved chemother-
apeutic agents to reduce or even eliminate specific instances of
drug resistance. This is particularly plausible for DNA-
directed agents, because cytochalasin B potentiates
multinucleation [2, 14]. Substantial multinucleation increases
the likelihood of apoptosis, as it takes only a single nucleus to
undergo programmed cell death before a chain reaction is
triggered, culminating in the destruction of the cell [21].
P388/ADR murine leukemia is well known for its resistance
to doxorubicin (trade name: Adriamycin, ADR) due to an
overexpression of P-gp [22–24]. ADR is an anthracycline that
intercalates DNA, thereby inhibiting topoisomerase II from
relaxing DNA supercoiling during transcription [16].
As such, it is likely that cytochalasin B administered con-
comitantly with ADR will produce substantial drug synergy,
potentially reversing ADR-resistance in P388/ADR cells.
However, cytochalasin B also has the propensity to inhibit
glucose transport [25–27]. Glucose transport inhibition has
been shown to decrease drug efflux in vincristine-resistant
murine erythroleukemia PC4 cell lines [28]. Using 21, 22-
dihydrocytochalasin B (DiHCB), a congener that has very
similar effects on microfilaments without notable glucose
transport inhibition [29, 30], concurrently with ADR should
help determine whether glucose transport inhibition has any
bearing on cytochalasin/ADR drug synergy.
Although not as well-studied as cytochalasin B, its conge-
ner cytochalasin D has also demonstrated marked anticancer
activity [31–33]. It has been observed in vitro that cytochala-
sin D is a much more potent inhibitor of actin polymerization
[34], suggesting that the in vivo dosage needs to be consider-
ably reduced to avoid excessive toxicity. In fact, cytochalasin
B and the reduced congener DiHCB are both 20-fold less
toxic than cytochalasin D in mice [35]. Nevertheless, cyto-
chalasin D has demonstrated anticancer activity against mul-
tiple cell lines in vitro [29, 30], warranting further in vivo
characterization. Although cytochalasins B and D have been
examined in vivo against solid malignancies [4, 33], neither
agent has been tested in vivo against disseminated hemato-
logical malignancies, and such data would be pivotal for
characterizing the extent of cancers that might possibly be
treated with microfilament-directed agents. Whether or not
cytochalasin D would potentiate drug synergy with ADR, or
other clinically approved chemotherapeutic agents is unclear,
as the congener has yet to be examined for drug synergy.
Therefore, it too is used in combination with ADR against
P388/ADR leukemia in this study.
Knowledge of the effects of cytochalasins as single agents
and optimization of any observed anticancer activity in vitro
or in vivo is important in itself, and essential for the design and
evaluation of studies involving the potential use of cytochala-
sin congeners as amplifiers of the activity of known chemo-
therapeutic agents in vivo. Therefore, this study seeks to
determine: 1) whether cytochalasin B exerts potentially useful
cytotoxicity on adherent carcinoma and melanoma, including
sub-lines selected for metastatic capacity, as well as on sus-
pension leukemia cells; 2) whether concomitant cytochalasin
B/ADR, DiHCB/ADR, or cytochalasin D/ADR treatment
against P388/ADR leukemia produces significant drug syner-
gy; and 3) whether cytochalasins B and D are efficacious
in vivo in prolonging the life of Balb/c mice challenged with
P388/S and P388/ADR leukemias.
Materials and methods
Conversion of in vivo intradermal passaged M109
to continuous culture (M109c)
A cell suspension (1×106 in 1 ml) derived from an in vivo
passaged intradermal (i.d.) tumor was inoculated into 25 cm2
culture flasks, and suspended in 9 ml of RPMI 1640 complete
medium containing 10% newborn calf serum (GIBCO, Grand
Island, NY), 0.4 units/ml penicillin, 0.4 μl/ml streptomycin,
and 250 μg/ml fungizone. Flasks were incubated in 5 % CO2
at 37 °C for 6 days with one medium change at 3 days. For
sub-culturing, the attached cells were trypsinized with 0.2 %
trypsin-EDTA solution 10X (Sigma-Aldrich Corp., St. Louis,
MO, USA) for 1 min at 37 °C, dislodged by a sharp knocking
of the flasks during that period, washed, diluted to 10 ml with
fresh complete medium, and 1×106 cells seeded into 25 cm2
culture flasks (4×104 cells/cm2). Floating colonies were ob-
served during growth. These proved to be 20 % trypan blue
negative, showed low tumorigenicity, and were not used.
After ten subculture passages over a period of 2 months,
the attached M109 cells (M109c cells) achieved
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morphological stability and grew to confluency (2×105 cells/
cm2) in 6 days when subcultured at 4×104 cells/cm2. Com-
parison between Balb/c mice challenged i.d. withM109c cells
and matched groups challenged with in vivo passaged M109
cells showed that the challenges were indistinguishable in
terms of growth kinetics, invasion, metastasis, and host sur-
vival. M109c retained in vitro and in vivo properties after
7 months of continuous passage in culture.
Cytochalasin B preparation
Cytochalasin B was prepared frommold mattes ofDrechslera
dematioidea (ATCC 24346) as previously described [3, 4],
and purified by preparative thin layer chromatography to
greater than 99 % homogeneity after recrystallization from
chloroform.
21, 22-dihydrocytochalasin B preparation
DiHCB was prepared by sodium-borohydride reduction of
cytochalasin B in methanol at 25 °C. The product was recov-
ered as a chloroform-soluble fraction and crystallized from
benzene:hexane. DiHCB was compared to a commercially
purchased sample of DiHCB (Sigma-Aldrich Corp.) and cy-
tochalasin B (Poniard Pharmaceuticals, San Francisco, CA,
USA) using reverse phase thin layer chromatography. The
product was also characterized with 1H NMR spectroscopy
(data not shown).
Cytochalasin D preparation
Cytochalasin D was prepared from mold mattes of
Zygosporium masonii (ATCC MYA 3308), and purified by
preparative thin layer chromatography to greater than 99 %
homogeneity after recrystallization from chloroform.
Effect of cytochalasin B on cancer cell lines in vitro
The attached cell lines M109c, B16BL6, and B16F10 were
seeded at 1 to 4×104 cells/ml in 2 ml volumes in 24-well
culture plates 1 day prior to treatment with cytochalasin B.
Conditions for treatment of the attached cell lines were as
detailed earlier for B16BL6 and B16F10 cells [4]. The sus-
pension culture of P388/ADR cells was seeded at 5×104 cells/
ml and allowed to grow overnight before cytochalasin B
treatment. Cells were treated with cytochalasin B for 3 h, as
well as 2, 3, or 4 days. In the case of continuous exposure for
2, 3, or 4 days, attached cells were trypsinized and counted
with a hemacytometer. Leukemia cell suspensions were
counted with a Coulter Counter. In the case of short-term
exposure, cells were washed twice with fresh medium, then
trypsinized (except for P388/ADR cells), reseeded, and
allowed to regrow for 3 days, at which time they were
counted. Growth results were calculated as the number of
cells generated above the seeding density compared to the
untreated control cells and graphically presented as percent of
control increase.
M109c clonogenic cells were determined by seeding ali-
quots containing 400–2000 trypsinized cells from each well
into wells in another 24-well plate, culturing for 7 days, fixing
in methanol (5 min), and staining with 0.1 % methylene blue
(5 min). Colonies of greater than 10 cells were counted with a
dissecting microscope.
Determining the extent of drug synergy between cytochalasins
and doxorubicin
To assess whether cytochalasin B, D or DiHCB synergizes
with ADR, cells were treated with a cytochalasin congener for
2.5 h over a concentration range of 0 to 150 μM, followed by
ADR over a concentration range of 0 to 9 μM for 3 h. IC50 and
IC80 values were taken at a series of concentrations for each
chemotherapeutic agent in order to construct an isobologram.
IC50 and IC80 values for the single agents and for combina-
tions were determined by MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assays.
In addition, drug synergy was assessed by clonogenic
assays in which P388/ADR cells were seeded in 24-well
plates at early log phase. Cytochalasin B or DiHCB were
administered for 2.5 h, followed by ADR for 3 h at a series
of concentrations. Aliquots of the treated cells were then
removed and cloned in soft agar in additional 24-well plates.
Results from the assays were plotted as log surviving fractions
at a given cytochalasin concentration as a function of ADR
concentration. Fold-synergism was then calculated at relative-
ly low concentrations of cyotchalasin where cytochalasin B or
DiHCB-alone had minimal influence on cloning efficiency.
P388 leukemias in vivo
For chemotherapy testing, Balb/c mice under isoflurane anes-
thesia (Sigma-Aldrich Corp.) were challenged with 2×105
trypan blue negative P388/S or P388/ADR cells subcutane-
ously (s.c.) in a volume of 200 μl. Untreated mice were kept in
order to determine the lethality of the challenge without che-
motherapeutic intervention. Long-term survival was defined
as challenged mice that survived the duration of the observa-
tion period.
Cytochalasins B and D intraperitoneal administration
Cytochalasins B and D were prepared in suspension form in
2 % carboxymethyl cellulose 1 % tween 20 (CMC/Tw) for
intraperitoneal (i.p.) administration, as previously described
[3, 4]. The congeners or the vehicle were administered to
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leukemia-challenged mice on Days 1–8 following the initial
challenge.
Statistics
Survival analysis used the Cox-Mantel test as detailed
by Lee [36]. Test of hypotheses for between subjects
effects were applied, and of time vs. group interactions
using the Geisser-Greenhouse adjustment in cases where
tests of orthogonal components showed absence of
sphericity.
Results
Effects of cytochalasin B treatment in vitro on M109c,
P388/ADR, B16BL6, and B16F10
The effects of continuous exposure to cytochalasin B for 3 and
4 days in vitro were determined for M109c and compared to
values obtained with two other attached murine tumor lines,
B16F10 and B16BL6 melanoma, and with a suspension cul-
ture of murine P388/ADR leukemia cells. The effects of 3 day
exposure are shown in Fig. 1a, while the IC50 and IC80 values
for 3 h, as well as for 2, 3, and 4 day exposures are presented in
Table 1. B16BL6 and P388/ADR are relatively resistant to CB
treatment (IC50 values approximately 5 uM for 3-day expo-
sure). M109c shows an IC50 after 3 days of exposure of 2 μM.
The remarkable sensitivity of the B16F10 line which is se-
lected by repeated in vivo subculture for ten sequential chal-
lenges from metastatic foci of B16BL6 malignant melanoma
is striking and potentially important. The IC50 for B16F10
melanoma is 0.4 μM, fully ten-fold more cytotoxic than for
the non-selected original B16BL6 line. This may point to
special efficacy of microfilament-directed agents for highly
metastatic selected cell lines.
Effects of cytochalasin B treatment for 3 h in vitro
on P388/ADR, M109c, and B16BL6
Since in vivo tolerated exposure to bioactive concentrations of
cytochalasin B administered systemically in the absence of
sustained release formulation is likely to be a matter of hours
rather than days [3, 4], we examined the short-term (3 h)
effects of cytochalasin B on P388/ADR, M109c and
B16BL6 cells (Fig. 1b). The IC50 and IC80 values are
presented in Table 1, and are compared with values
obtained for the P388/ADR line, as well as the parental
drug-sensitive P388 line we have previously determined
(unpublished data). P388/ADR and B16BL6 show po-
tent resistance to cytochalasin B with 3-hour IC50
values in the range of 30 μM. M109c showed a 10-
fold higher sensitivity to cytochalasin B with an IC50
after 3 h of 3 μM. The comparative toxicities of
cytchalasin B and ADR against M109c cells in a 3 h
exposure are also presented in Fig. 1b. It is apparent
that cytochalasin B is 14-fold less cytotoxic in terms of
comparative IC50 values against M109c cells than is ADR,
confirming the comparatively low cytotoxicity of short-term
cytochalasin B exposure.
Fig. 1 Cytochalasin B against multiple murine cancer cell lines in vitro. a
Effects of 3-day continuous exposure to cytochalasin B on growth of
attached and suspension culture murine neoplastic cell lines. Continuous
cell lines as indicated in the figure were seeded at 4 to 8×104 cells per
well (2 to 4×104 cells/cm2) for attached cells in 2 ml (triplicate, 24 well-
plates, complete medium; see materials and methods), and were allowed
to attach overnight. P388/ADR cells were seeded at 5×104 cells/ml in
2 ml of medium, and allowed to grow overnight. Cells were continuously
exposed to cytochalasin B (CB) at concentrations shown for 3 days at
37 °C in 5 % CO2 in a humidified atmosphere. Attached cells (B16BL6,
B16F10, and M109c) were washed, trypsinized, and counted with a
hemacytometer. P388/ADR suspensions were counted with a Coulter
counter. The increase in cell number beyond the number present at the
time of treatment initiationwas compared to the increase in cell number in
the corresponding controls. b Effects of short-term, 3 h exposure to
cytochalasin B on growth of attached and suspension culture neoplastic
cell lines. Cell lines were seeded as detailed in Fig. 1a, but treated with CB
at the concentrations shown for only 3 h
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Extent of drug synergy between cytochalasins
and doxorubicin against P388/ADR leukemia
Despite the lower activity of cytochalasin B in P388/ADR
leukemia, it still produced a substantial synergistic effect with
ADR against the ADR-resistant cell line, as assessed by the
IC50 (Fig. 2a) and IC80 (Fig. 3a) isobolograms. While low
concentrations of cytochalasin B demonstrated marked syner-
gy in the IC80 isobologram, it took a 150μMconcentration for
cytochalasin B by itself to reach the IC80 inhibition point.
(Fig. 3a). This pattern was also seen in the IC99 cloning
isobologram for cytochalasin B/ADR (Fig. 4) where 1.1 mM
cytochalasin B is required to reach the IC99 value with the
single agent treatment. DiHCB also demonstrated consider-
able drug synergy with ADR against P388/ADR leukemia,
with a smooth curve well under the additivity line being
observed in both the IC50 and IC80 isobolograms (Figs. 2b
and 3b). Cytochalasin D demonstrated little to no synergy
with ADR against P388/ADR leukemia (Figs. 2c and 3c).
Nevertheless, cytochalasin D appeared to be intermediate
between DiHCB and cytochalasin B in regards to inhibiting
growth as single agents at their IC50 and IC80 values. DiHCB
Table 1 Effects of cytochalasin B against murine cancer lines in vitro
CB exposure time 3 h 2 days 3 days 4 days
IC concentrations (μM) IC50 IC80 IC50 IC80 IC50 IC80 IC50 IC80
M109c 2.56 12.23 0.83 6.02 0.42 3.77 0.25 0.75
B16F10 ND ND 0.80 3.50 0.46 1.59 0.37 1.21
B16BL6 10.46 44.86 2.10 20.04 0.96 17.03 0.87 10.41
P388/ADR 105.5 188.4 6.23 10.45 4.24 6.47 ND ND
P388/S 51.9 84.1a 3.10 5.02 ND ND ND ND
ND Not determined, a 2.5 h
Fig. 2 IC50 Isobolograms of cytochalasins and doxorubicin to determine extent of drug synergy against P388/ADR leukemia. aCB andADR. bDiHCB
and ADR. c CD and ADR
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produced IC50 and IC80 inhibitions at 28 μM and 48 μM
respectively. Cytochalasin B required 100 μM and 150 μM
to reach IC50 and IC80. Cytochalasin D required 42 μM and
68 μM to reach IC50 and IC80 respectively. (Figs. 2 and 3).
The extent of drug synergy potentiated by cytochalasin B
and DiHCB was further evaluated in log surviving fraction
cloning assays comparing the parent compound (cytochalasin
B) against its reduced congener (DiHCB) in eliciting drug
synergy with ADR (Fig. 5). Differences in the extent of drug
synergy were readily apparent. DiHCB appeared to synergize
much more effectively with ADR, as it produced a lower log
surviving fraction at much lower concentrations (1 to 10 μM)
than did cytochalasin B (2 to 40 μM). For example, at 8 μM
ADR, 40 μM cytochalasin B produced a log fraction of −2.4
against P388/ADR leukemia cells. By contrast, only 10 μM
DiHCB was needed to produce a log fraction of −3.19 when
combined with the same concentration of ADR. Therefore, a
lower concentration of DiHCB was able to elicit a stronger
synergistic effect than did its oxidized congener.
Effects of cytochalasins B and D against P388 leukemias
in vivo
Cytochalasin B appeared to increase the life expectancy of
Balb/c mice challenged with either P388/ADR or P388/S
leukemias (Fig. 6). It was discerned from the P388/ADR
protocol that Balb/c mice could take up to 50 mg/kg/day i.p.
for eight consecutive days (Days 1–8). Therefore, only this
dose was examined for P388/S challenged mice, as the
Fig. 3 IC80 Isobolograms of cytochalasins and doxorubicin to determine extent of drug synergy against P388/ADR leukemia. aCB andADR. bDiHCB
and ADR. c CD and ADR
Fig. 4 IC99 Cloning isobologram of cytochalasin B and doxorubicin to
determine extent of drug synergy against P388/ADR leukemia. Values of
cytochalasin B are provided in the figure to clarify each point
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antitumor activity of cytochalasin B appeared to be dose
dependent. Interestingly, 50 mg/kg cytochalasin B was able
to produce 10 % long-term survival in the multidrug resistant
P388/ADR cohort, and 40 % long-term survival in the drug
sensitive P388/S cohort.
The antitumor effects of cytochalasin B were mirrored by
cytochalasin D at much lower concentrations (Fig. 6b). It only
took 2 mg/kg/day cytochalasin D administered for eight con-
secutive days (Days 1–8) to produce marked prolongation in
the life expectancy of mice challenged with P388/S, as well as
a 20 % long-term survival rate. Whether or not cytochalasin D
would exhibit the same antitumor effect against P388/ADR at
these lower concentrations remains unclear, as not enough
mice remained to establish another treatment group of suffi-
cient quantity. Nevertheless, it is likely that at least some
prolongation in life expectancy would be observed. The cyto-
chalasin vehicle CMC/Tw did not affect the life span of mice
challenged with either leukemia, demonstrating that there is
no effect of the lipophilic detergent vehicle on the leukemia
challenges in the absence of cytochalasins.
Discussion
In the present study, we have demonstrated that cytochalasin
B is 14-fold less cytotoxic against M109c cells than is ADR in
a 3 h exposure assay when the washed cells are allowed to
regrow, and the respective IC50 values are evaluated. These
data further support that cytochalasin B is only moderately
cytotoxic [3, 4]. It is worth noting that cytochalasin B is
relatively more cytotoxic in vitro against attached cell lines
(Table 1 and Fig. 1) than against a suspension culture, partic-
ularly in 3 h drug comparisons. It should also be noted that
Fig. 5 Comparison of
doxorubicin drug synergy
between cytochalasin B and 21,
22-dihydrocytochalasin B against
P388/ADR leukemia assessed by
log surviving fraction cloning
assays. a Cloning assay for
concomitant DiHCB/ADR




concentrations for 3 h
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among the attached neoplastic cell lines, there is variable
sensitivity to cytochalasin B, indicating that the effects of
the agent in vitro are not solely related to nonspecific alter-
ations in adherence to the substrate. In particular, cytochalasin
B was much more cytotoxic against B16F10 than B16BL6.
B16F10 is a highly metastatic variant of B16 murine melano-
ma that is selected for its propensity tometastasize to the lungs
by serial passaging beginning with B16BL6, and then passag-
ing from lung metastases ten times in vivo [37–39]. We have
previously demonstrated that cytochalasin B is markedly cy-
totoxic against B16F10 in vitro [4], and this direct comparison
against a less metastatic variant (B16BL6) intriguingly sug-
gests that cytochalasin B may have a profound inhibitory
effect on highly metastatic cells.
Cytochalasin B and DiHCB-mediated drug synergy war-
rant further investigation based on the in vitro data. As
assessed by isobolographic analysis, it was apparent that
cytochalasin B and DiHCB synergize with ADR against
ADR-resistant P388/ADR leukemia (Figs. 2 and 3), a cell line
in which neither of the cytochalasin congeners, nor ADR
show substantial inhibitory activity alone. DiHCB/ADR treat-
ments (Fig. 5a) were able to produce a lower log surviving
fraction of P388/ADR leukemia cells than was the combina-
tion of cytochalasin B/ADR (Fig. 5b), showing that DiHCB
synergizes more efficiently with ADR than does cytochalasin
B. These data also indicate that cytochalasin synergy with
ADR is not dependent on inhibiting glucose transport, as
DiHCB, which does not affect glucose transport was a more
effective synergizing agent. Nevertheless, both compounds
substantially improved the efficacy of ADR treatments in an
ADR-resistant cell line, warranting further investigation of
concomitant cytochalasin therapies. In fact, cytochalasin B
Fig. 6 Cytochalasins against
P388/ADR and P388/S murine
leukemias in vivo. a Effects of
intraperitoneally administered
cytochalasin B on the survival of
P388/ADR murine leukemia-
challenged mice. Cytochalasin B
was administered at 10, 25, or
50 mg/kg, while the CMC/Tw
vehicle was administered at
0.1 ml. The treatments were
administered on Days 1–8
following the leukemia challenge.
b Effects of intraperitoneally
administered cytochalasin B or D
on the survival of P388/S murine
leukemia-challenged mice.
Cytochalasin B was administered
at 50 mg/kg, and cytochalasin D
was administered at 0.25, 0.5, 1,
or 2 mg/kg. The CMC/Tw vehicle
was again administered at 0.1 ml.
The treatments were administered
on Days 1–8 following the
leukemia challenge. The number
of mice per each treatment group
is provided in both panels.
Survival of mice in all treatment
groups was significantly different
from controls left untreated or
treated only with the vehicle
(CMC/Tw) in both panels;
p<0.05, as assessed by a Cox-
Mantel test
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has already been shown to synergize with cytarabine [40] and
vincristine [41], suggesting that this, and potentially other
cytochalasin congeners, may be used to supplement current
chemotherapeutic protocols.
This study marks the first time that either cytochalasin B or
D was shown to have significant antitumor activity against
leukemia in vivo. Although P388/ADR leukemia is known to
be a multidrug resistant cell line [42–44], cytochalasin B was
still able to exert marked antitumor activity (Fig. 6a), demon-
strating that the novel mechanisms by which the compound
perturbs neoplastic cells can inhibit the progression of dissem-
inated hematological cancers. As expected, more antitumor
activity was observed in mice challenged with drug sensitive
P388/S leukemia, and nearly half of the treatment group
achieved long-term survival when treated with 50 mg/kg/
day i.p. cytochalasin B for eight consecutive days (Fig. 6b).
Due to the increased cytotoxicity of cytochalasin D, only
2 mg/kg/day i.p. for the same time period could be used in
mice, but this lower dose level was still able to exert substan-
tial antitumor effects, with 20 % of the treatment group
achieving long-term survival (Fig. 6b).
From these data, it can be surmised that cytochalasins exert
substantial anticancer activity in vitro and in vivo, and could
likely be used in combination with currently approved anti-
neoplastic agents. We have already demonstrated that cyto-
chalasin B elicits marked antitumor activity against murine
M109 lung carcinoma and murine B16 melanoma in vivo [3].
The in vivo effects of cytochalasin B and a liposome encap-
sulated derivative are further characterized against M109 lung
carcinoma in the subsequent paper of this series [45], provid-
ing additional evidence for the clinical potential of
microfilament-directed agents.
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